This article is more than 5 years old. Information may no longer be current.

InMed seeks to protect patent for cannabinoid glaucoma formulation

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

InMed Pharmaceuticals has filed a Patent Cooperation Treaty application for INM-085, a cannabinoid-based therapy for the topical treatment of glaucoma, the company announced in a press release.

The filing would include protection of InMed’s technology in 150 countries, including the United States, and has a priority date from May 8, 2018, the release said.

“With the filing of this patent application, we are continuing the process of pursuing commercial protection for our novel technologies, in this case until May 2038. This is particularly important to the company as we undertake additional preclinical studies of INM-085, as well as pursue initial discussion with potential partners,” Eric A. Adams, InMed president and CEO, said in the release.

INM-085 is a topical therapy designed to reduce IOP, intended for application once per day.